Trade 3SBio Inc. - 1530 CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.30 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.021963% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.000045% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | HKD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | Hong Kong | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.7 |
| Open | 5.6 |
| 1-Year Change | -26.32% |
| Day's Range | 5.6 - 5.95 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 5.95 | 0.30 | 5.31% | 5.65 | 5.95 | 5.55 |
| Apr 24, 2024 | 5.70 | 0.15 | 2.70% | 5.55 | 5.75 | 5.50 |
| Apr 23, 2024 | 5.55 | 0.15 | 2.78% | 5.40 | 5.65 | 5.40 |
| Apr 22, 2024 | 5.45 | 0.05 | 0.93% | 5.40 | 5.50 | 5.35 |
| Apr 19, 2024 | 5.40 | -0.05 | -0.92% | 5.45 | 5.45 | 5.35 |
| Apr 18, 2024 | 5.50 | 0.05 | 0.92% | 5.45 | 5.55 | 5.40 |
| Apr 17, 2024 | 5.45 | 0.00 | 0.00% | 5.45 | 5.50 | 5.35 |
| Apr 16, 2024 | 5.45 | -0.20 | -3.54% | 5.65 | 5.75 | 5.45 |
| Apr 15, 2024 | 5.70 | -0.05 | -0.87% | 5.75 | 5.80 | 5.65 |
| Apr 12, 2024 | 5.80 | -0.05 | -0.85% | 5.85 | 5.90 | 5.75 |
| Apr 11, 2024 | 5.85 | 0.05 | 0.86% | 5.80 | 5.90 | 5.75 |
| Apr 10, 2024 | 5.90 | -0.20 | -3.28% | 6.10 | 6.15 | 5.85 |
| Apr 9, 2024 | 6.15 | 0.30 | 5.13% | 5.85 | 6.20 | 5.85 |
| Apr 8, 2024 | 5.90 | 0.05 | 0.85% | 5.85 | 5.95 | 5.75 |
| Apr 5, 2024 | 5.85 | -0.10 | -1.68% | 5.95 | 5.95 | 5.70 |
| Apr 3, 2024 | 5.95 | 0.05 | 0.85% | 5.90 | 6.00 | 5.85 |
| Apr 2, 2024 | 5.90 | 0.10 | 1.72% | 5.80 | 6.00 | 5.70 |
| Mar 28, 2024 | 5.85 | 0.20 | 3.54% | 5.65 | 5.90 | 5.50 |
| Mar 27, 2024 | 5.60 | -0.15 | -2.61% | 5.75 | 5.75 | 5.55 |
| Mar 26, 2024 | 5.75 | -0.10 | -1.71% | 5.85 | 5.90 | 5.75 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
3SBio Company profile
3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. The company's primary products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; Yisaipu, a tumour necrosis factor for treating rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and EPIAO, a recombinant human erythropoietin for the treatment of anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia, and reduction of allogeneic blood transfusion in surgery patients. Its primary products also comprise SEPO, a recombinant human erythropoietin for anemia associated with CKD and chemotherapy; Byetta/Bydureon, an exenatide injection to improve glycemic control in adults with type-2 diabetes mellitus; and Qiming Keli for retinopathy caused by type-2 diabetes. In addition, the company offers Ruisiyi to treat advanced breast cancer; Wanwei for treating vomiting caused by cytotoxic chemotherapy; and Intefen to treat lymphatic or hematopoietic malignancies and viral infections. Further, it provides Inleusin for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; Etanercept for moderate to severe rheumatoid arthritis and plaque psoriasis, and active ankylosing spondylitis; and Sparin for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. Additionally, the company offers Mandi for male-pattern alopecia and alopecia areata; Aiyishu for iron-deficiency anemia; Disu to prevent and treat chronic bronchitis, colds, and asthma; Jiannipai to prevent acute rejection after renal transplantation; and Humulin for diabetes, as well as contract development and manufacturing, trading, project management and consultation, and technology services. The company markets its products through in-house sales and marketing team, as well as distributors and third-party promoters. 3SBio Inc. was incorporated in 2006 and is headquartered in Shenyang, the People's Republic of China.| Industry: | Biopharmaceuticals |
瀋陽經濟技術開發區十號路1甲3號
SHENYANG
LIAONING
CN
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com